Skip to main
  1. Stocks
  2. LeonaBio Inc
  3. Forecast
LONA

LeonaBio Inc (LONA) Stock Forecast & Price Target

LeonaBio Inc (LONA) Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 0%
Buy 100%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

LeonaBio is positioned favorably because its lead lasofoxifene program is already in an advanced Phase 3 study, with >80% of 600 patients enrolled and completion expected in 4Q26, while top-line results are anticipated in 2H27. The investment case is strengthened by prior Phase 2 ELAINE-2 data showing a competitive 13-month progression-free survival and an attractive safety profile, plus expert support in April 2026 highlighting tolerability as a key differentiator in heavily pretreated ER+/HER2-, ESR1-mutated advanced breast cancer. Financially, the company appears well-funded to execute the program, ending 3Q26 with approximately $32MM in cash, while its ALS asset brelgometon showed favorable Phase 1 safety, tolerability, dose-proportional PK, and CNS penetration, supporting further pipeline optionality.

Bears say

LeonaBio is exposed to substantial clinical, regulatory, and commercialization risk because its pipeline candidates still require additional development before any filing or approval, and the FDA could reject them for data or manufacturing deficiencies. Competitive pressure is also meaningful, since approved disease-modifying and symptomatic agents in Alzheimer’s include generic options that can limit pricing power, while patent or exclusivity challenges to Brelgometon (ATH-1105) and other candidates could weaken future sales. Financially, the company is expected to continue incurring net losses until product approval and likely through the early launch phase, and may need additional capital that could dilute shareholder value.

LeonaBio Inc (LONA) has been analyzed by 3 analysts, with a consensus rating of Buy. 0% of analysts recommend a Strong Buy, 100% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of LeonaBio Inc and is not a guaranteed prediction by Public.com or investment advice.

LeonaBio Inc (LONA) Analyst Forecast & Price Prediction

Get the latest LeonaBio Inc (LONA) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in LeonaBio Inc (LONA)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About LeonaBio Inc (LONA) Forecast

Analysts have given LeonaBio Inc (LONA) a Buy based on their latest research and market trends.

According to 3 analysts, LeonaBio Inc (LONA) has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $16, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $16, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

LeonaBio Inc (LONA)


LeonaBio Inc (LONA) Analyst Forecast & Price Prediction

Get the latest LeonaBio Inc (LONA) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in LeonaBio Inc (LONA)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover LONA stock data and trends